NEW YORK — Theradiag reported on Monday an 8 percent year-over-year increase in revenues for 2020 on strong sales of its theranostics products.
For the 12-month period ended Dec. 31, 2020, Theradiag's revenues rose to €10.4 million ($12.6 million) from €9.6 million the year before. Theranostics sales climbed almost 16 percent to €5.1 million from €4.4 million, with the company's Tracker line of therapeutic drug monitoring tests selling particularly well in the US, where the products are commercialized in collaboration with HalioDx.